GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Accolade Inc (NAS:ACCD) » Definitions » Graham Number

Accolade (Accolade) Graham Number : $N/A (As of Nov. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Accolade Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2024-04-28), the stock price of Accolade is $7.89. Accolade's graham number for the quarter that ended in Nov. 2023 was $N/A. Therefore, Accolade's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Accolade's Graham Number or its related term are showing as below:

ACCD's Price-to-Graham-Number is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.075
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Accolade Graham Number Historical Data

The historical data trend for Accolade's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accolade Graham Number Chart

Accolade Annual Data
Trend Feb18 Feb19 Feb20 Feb21 Feb22 Feb23
Graham Number
Get a 7-Day Free Trial - - - - -

Accolade Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Accolade's Graham Number

For the Health Information Services subindustry, Accolade's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accolade's Price-to-Graham-Number Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Accolade's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Accolade's Price-to-Graham-Number falls into.



Accolade Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Accolade's Graham Number for the fiscal year that ended in Feb. 2023 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*-0.104*-2.279)
=N/A

Accolade's Graham Number for the quarter that ended in Nov. 2023 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*-0.234*-1.655)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accolade  (NAS:ACCD) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Accolade's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Nov. 2023 )
=7.89/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Accolade Graham Number Related Terms

Thank you for viewing the detailed overview of Accolade's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


Accolade (Accolade) Business Description

Traded in Other Exchanges
Address
1201 Third Avenue, Suite 1700, Seattle, WA, USA, 98101
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. It generates revenue by providing personalized health guidance solutions to members.
Executives
Richard Eskew officer: EVP General Counsel C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Stephen H. Barnes officer: Chief Financial Officer C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Rajeev Singh director, officer: Chief Executive Officer 6222 185TH AVENUE NE, REDMOND WA 98052
Robert N Cavanaugh officer: President 1601 CLOVERFIELD BLVD., SUITE 620, SANTA MONICA CA 90404
Mchugh Colin officer: Chief Accounting Officer C/O ACCOLADE, INC., 660 W. GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Michael W Hilton officer: Chief Product Officer 6222 185TH AVE, REDMOND WA 98052
Peter S Klein director C/O MICROSOFT CORPORATION, ONE MICROSOFT WAY, REDMOND WA 98052-6399
Cindy Kent director 7601 PENN AVENUE SOUTH, RICHFIELD MN 55418
Patricia L Wadors director C/O ALIGN TECHNOLOGY INC, 881 MARTIN AVE, SANTA CLARA CA 95050
Dawn G Lepore director 1425 BROADWAY PMB 41, SEATTLE WA 99122
Jeffrey D Jordan director 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
Jeffrey S Brodsky director C/O MORGAN STANLEY 1585 BROADWAY, NEW YORK NY 10036
Thomas J Neff director SPENCER STUART & ASSOCIATES, 277 PARK AVE, NEW YORK NY 10172
William H. Frist director 600 MONTGOMERY STREET, SAN FRANCISCO CA 94111

Accolade (Accolade) Headlines

From GuruFocus

Accolade Announces Upcoming Investor Events

By sperokesalga sperokesalga 05-08-2023

Accolade Inc CEO Rajeev Singh Sells 1,578 Shares

By GuruFocus Research GuruFocus Editor 05-25-2023

Report: Employees are Overwhelmed, Delaying Care at High Rates

By PRNewswire PRNewswire 06-05-2023

Accolade to Announce Fiscal First Quarter 2024 Financial Results

By sperokesalga sperokesalga 06-13-2023